Chemistry:Devextinetug

From HandWiki

Devextinetug (INN, USAN; developmental code name IXT-m200) is a monoclonal antibody against methamphetamine which is under development for the treatment of substance-related disorders including methamphetamine overdose.[1][2][3] It is taken by intravenous injection.[1] The drug has been found to reduce the toxicity of methamphetamine in overdose, for instance reducing agitation and need for sedation.[2] Devextinetug is under development by InterveXion Therapeutics.[1] As of May 2024, it is in phase 2 clinical trials for substance-related disorders.[1]

See also

  • List of investigational substance-related disorder drugs

References

  1. ↑ 1.0 1.1 1.2 1.3 "InterveXion Therapeutics". 28 May 2024. https://adisinsight.springer.com/drugs/800036212. 
  2. ↑ 2.0 2.1 "Vaccines as Immunotherapies for Substance Use Disorders". The American Journal of Psychiatry 181 (5): 362–371. May 2024. doi:10.1176/appi.ajp.20230828. PMID 38706331. "Drug overdoses from a mixture of opioids and methamphetamine increased over eightfold between 2012 and 2019 (2, 59). Like CUD, no pharmacotherapies or vaccines are FDA approved for methamphetamine, as many clinical trials have failed. Intervexion has completed a 20-patient randomized, multisite, open-label, phase 2 study comparing their methamphetamine monoclonal (devextinetug) to treatment-asusual in patients with mild to moderate methamphetamine toxicity. One hour after dosing, 50% of treated patients (versus 25% control subjects) showed normalization of agitation and fewer needed to be sedated (31.3% vs. 75.0%) (60).". 
  3. ↑ "Comparison between a chimeric anti-methamphetamine monoclonal antibody and humanized antibodies on pharmacological effects of methamphetamine". Psychopharmacology. December 2025. doi:10.1007/s00213-025-06959-9. PMID 41384974.